Want to see REPL full AI Analyst Report?
REPL Stock Chart & Stats
$9.70
-$0.76(-7.27%)
At close: 4:00 PM EDT
$9.70
-$0.76(-7.27%)
Day’s Range― - ―
52-Week Range$1.50 - $12.50
Previous CloseN/A
Volume3.27M
Average Volume (3M)3.05M
Market Cap
$454.25M
Enterprise Value$475.48
Total Cash (Recent Filing)$268.89M
Total Debt (Recent Filing)$111.59M
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.38
Shares Outstanding84,026,070
10 Day Avg. Volume3,202,601
30 Day Avg. Volume3,049,337
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)4.27
Price to Sales (P/S)0.00
P/FCF Ratio-2.49
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.75Price Target Upside52.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.34
Revenue Forecast (FY)$27.60M
Bulls Say, Bears Say
Bulls Say
Proprietary Immulytic Platform And PipelineReplimune’s Immulytic platform and multiple programs (RP1/2/3) represent a durable R&D asset and competitive moat in oncolytic immunotherapy. A platform approach supports repeatable product generation, combination strategies with checkpoint inhibitors, and diversified clinical development across tumor types, preserving long-term upside if one program succeeds.
Regulatory Progress On RP1 With Advisory ReviewThe FDA’s acceptance of the RP1 BLA resubmission, an advisory committee review and a favorable 10-3 panel vote are structural regulatory milestones. Successful regulatory outcomes would convert Replimune from a pre-commercial developer into a potential commercial oncology company, materially changing its revenue and partnership dynamics over the medium term.
Relatively Modest Leverage On Balance SheetHistorically low debt versus equity gives Replimune financial flexibility to fund continued R&D either via non-debt financing or partnerships. While equity has fallen, limited leverage preserves capacity to raise capital and limits near-term solvency risk versus highly leveraged peers, supporting ongoing clinical programs over several quarters.
Bears Say
No Commercial Revenue; Accelerating Losses And Cash BurnReplimune currently lacks product revenue and shows accelerating operating losses and negative cash flow, which are durable constraints on self-sufficiency. Persistent cash burn obliges repeated capital raises or partnerships, increasing execution risk and potentially diverting management focus from clinical execution to financing over the medium term.
Sharp Erosion Of Equity/capital BaseThe rapid decline in shareholders’ equity reflects cumulative losses and reduces the company’s cushion against further setbacks. A shrunken capital base limits strategic optionality, increases the probability and potential size of dilutive financing, and heightens vulnerability to adverse trial or regulatory outcomes over the next several quarters.
Regulatory Uncertainty Tied To Single-arm IGNYTE EvidenceRP1’s approval pathway relies heavily on single-arm IGNYTE data, which regulators explicitly questioned. Dependence on non-randomized evidence increases the chance of restrictive label, additional post-approval requirements, or denial, leaving commercialization and reimbursement uncertain and creating sustained binary regulatory risk for the company’s long-term prospects.
Replimune Group News
REPL FAQ
What was Replimune Group’s price range in the past 12 months?
Replimune Group lowest stock price was $1.50 and its highest was $12.50 in the past 12 months.
What is Replimune Group’s market cap?
Replimune Group’s market cap is $454.25M.
When is Replimune Group’s upcoming earnings report date?
Replimune Group’s upcoming earnings report date is Aug 06, 2026 which is in 6 days.
How were Replimune Group’s earnings last quarter?
Replimune Group released its earnings results on Jun 29, 2026. The company reported -$0.76 earnings per share for the quarter, missing the consensus estimate of -$0.661 by -$0.099.
Is Replimune Group overvalued?
According to Wall Street analysts Replimune Group’s price is currently Undervalued.
Does Replimune Group pay dividends?
Replimune Group does not currently pay dividends.
What is Replimune Group’s EPS estimate?
Replimune Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Replimune Group have?
Replimune Group has 84,026,070 shares outstanding.
What happened to Replimune Group’s price movement after its last earnings report?
Replimune Group reported an EPS of -$0.76 in its last earnings report, missing expectations of -$0.661. Following the earnings report the stock price went down -3.697%.
Which hedge fund is a major shareholder of Replimune Group?
Currently, no hedge funds are holding shares in REPL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Replimune Group Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.75 (52.06% Upside)
$14.75 (52.06% Upside)
Blogger Sentiment
Bearish
REPL Sentiment 64%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 132.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $474.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 7.3%
Last 30 Days ▲ 7.3%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
212.90%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-39.71%
Trailing 12-Months
Company Description
Replimune Group
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
REPL Stock 12 Month Forecast
Average Price Target
$14.75
▲(52.06% Upside)
Technical Analysis
CytomX Therapeutics
―
Immatics
―
Lyell Immunopharma
―
Candel Therapeutics
―
Artiva Biotherapeutics, Inc.
―
Ownership Overview
3.49% Insiders
17.42% Mutual Funds
2.72% Other Institutional Investors
60.85% Public Companies and
Individual Investors